T Cell Line-Based Packaging Cell Line for the Production of Retroviruses by Enriching of Cd3 Expressing Cells
    4.
    发明申请
    T Cell Line-Based Packaging Cell Line for the Production of Retroviruses by Enriching of Cd3 Expressing Cells 审中-公开
    T细胞系包装细胞系通过丰富Cd3表达细胞生产逆转录病毒

    公开(公告)号:US20080201791A1

    公开(公告)日:2008-08-21

    申请号:US11917842

    申请日:2006-06-27

    IPC分类号: A01K67/027 C12N15/85 C12N5/10

    摘要: The present invention relates to retroviral vector systems, in particular the development of packaging or helper cell lines that are based on T cells and that are suitable for producing T cell receptor retroviruses. Thereby, the present invention relates to T cell line specific retroviral expression vectors, and mammalian T cell line-based helper cell lines. The invention further relates to methods for expressing transgenes and to T cell line specific retroviral vector systems, including biochemical kits, that utilize and/or comprise the T cell line specific retroviral expression vectors and/or mammalian T cell line-based helper cell lines.

    摘要翻译: 本发明涉及逆转录病毒载体系统,特别涉及基于T细胞并适用于产生T细胞受体逆转录病毒的包装或辅助细胞系的开发。 因此,本发明涉及T细胞系特异性逆转录病毒表达载体和哺乳动物T细胞系辅助细胞系。 本发明还涉及用于表达转基因和T细胞系特异性逆转录病毒载体系统的方法,包括生物化学试剂盒,其利用和/或包含T细胞系特异性逆转录病毒表达载体和/或哺乳动物T细胞系辅助细胞系。

    REPERTOIRE OF ALLO-RESTRICTED PEPTIDE-SPECIFIC T CELL RECEPTOR SEQUENCES AND USE THEREOF
    6.
    发明申请
    REPERTOIRE OF ALLO-RESTRICTED PEPTIDE-SPECIFIC T CELL RECEPTOR SEQUENCES AND USE THEREOF 有权
    ALLO-限制性肽特异性T细胞受体序列的替代物及其用途

    公开(公告)号:US20120128704A1

    公开(公告)日:2012-05-24

    申请号:US13148653

    申请日:2010-02-09

    CPC分类号: C07K14/7051 C07K14/70503

    摘要: The present invention is directed to a kit-of-parts or composition containing nucleic acid sequences coding for high-avidity, allo-restricted TCR, wherein the TCR are independently directed against the tyrosinase antigen, the melan-A antigen and the survivin antigen. The invention is further directed to a kit-of-parts or composition containing at least three groups of transgenic lymphocytes transformed with vectors coding for TCR against said antigens. Furthermore, the present invention provides a pharmaceutical composition and its use in the treatment of diseases involving malignant cells expressing said tumor-associated antigens. The invention further relates to a nucleic acid molecule coding for a TCR that recognizes the survivin antigen, a TCR encoded thereby and a T cell expressing said TCR. Further, the invention discloses a vector, a cell and a pharmaceutical composition encoding/containing same and their use in the treatment of diseases involving malignant cells expressing survivin.

    摘要翻译: 本发明涉及包含编码高亲合力,同种异体限制性TCR的核酸序列的成套工具或组合物,其中TCR独立地针对酪氨酸酶抗原,黑色素A抗原和存活蛋白抗原。 本发明还涉及包含至少三组转基因淋巴细胞的试剂盒或组合物,所述转基因淋巴细胞用编码针对所述抗原的TCR的载体转化。 此外,本发明提供药物组合物及其在治疗涉及表达所述肿瘤相关抗原的恶性细胞的疾病中的用途。 本发明还涉及编码识别存活蛋白抗原的TCR的核酸分子,由此编码的TCR和表达所述TCR的T细胞。 此外,本发明公开了一种载体,细胞和编码/含有它们的药物组合物及其在治疗涉及表达存活蛋白的恶性细胞的疾病中的用途。

    Repertoire of allo-restricted peptide-specific T cell receptor sequences and use thereof
    7.
    发明授权
    Repertoire of allo-restricted peptide-specific T cell receptor sequences and use thereof 有权
    同种异体限制性肽特异性T细胞受体序列的汇编及其用途

    公开(公告)号:US09409969B2

    公开(公告)日:2016-08-09

    申请号:US13148653

    申请日:2010-02-09

    IPC分类号: C07H21/04 C07K14/705

    CPC分类号: C07K14/7051 C07K14/70503

    摘要: The present invention is directed to a kit-of-parts or composition containing nucleic acid sequences coding for high-avidity, allo-restricted TCR, wherein the TCR are independently directed against the tyrosinase antigen, the melan-A antigen and the survivin antigen. The invention is further directed to a kit-of-parts or composition containing at least three groups of transgenic lymphocytes transformed with vectors coding for TCR against said antigens. Furthermore, the present invention provides a pharmaceutical composition and its use in the treatment of diseases involving malignant cells expressing said tumor-associated antigens. The invention further relates to a nucleic acid molecule coding for a TCR that recognizes the survivin antigen, a TCR encoded thereby and a T cell expressing said TCR. Further, the invention discloses a vector, a cell and a pharmaceutical composition encoding/containing same and their use in the treatment of diseases involving malignant cells expressing survivin.

    摘要翻译: 本发明涉及包含编码高亲合力,同种异体限制性TCR的核酸序列的成套工具或组合物,其中TCR独立地针对酪氨酸酶抗原,黑色素A抗原和存活蛋白抗原。 本发明还涉及包含至少三组转基因淋巴细胞的试剂盒或组合物,所述转基因淋巴细胞用编码针对所述抗原的TCR的载体转化。 此外,本发明提供药物组合物及其在治疗涉及表达所述肿瘤相关抗原的恶性细胞的疾病中的用途。 本发明还涉及编码识别存活蛋白抗原的TCR的核酸分子,由此编码的TCR和表达所述TCR的T细胞。 此外,本发明公开了一种载体,细胞和编码/含有它们的药物组合物及其在治疗涉及表达存活蛋白的恶性细胞的疾病中的用途。